Flint A, Lloyd R V
Pathol Annu. 1990;25 Pt 1:37-52.
The difference in biologic behavior of Hürthle-cell neoplasms as reported in several series may be explained by the use of different diagnostic pathologic criteria, and the selection of patients with neoplasms of varying clinical stages (treatment at the time of initial diagnosis versus treatment for advanced disease, or initial diagnosis at an advanced stage). On the basis of all of the available evidence, it appears that Hürthle-cell neoplasms exhibit a biologic behavior similar to that of corresponding follicular neoplasms although these latter tumors may have a slightly higher propensity to metastasize. Survival and cure rates are lower than those for papillary cancer and are comparable to those for follicular carcinoma. DNA analysis may be of some help in predicting clinical behavior; aneuploid neoplasms are more often associated with the pathologic features of malignant tumors and may follow a more aggressive clinical course. At present, however, we are unaware of specific surgical strategies that are based upon DNA analysis. Tumor size and morphometric analysis of cytological features have not been particularly valuable for estimating the clinical course of these tumors.
几个系列报道的许特莱细胞肿瘤生物学行为的差异，可能是由于使用了不同的诊断病理标准，以及选择了不同临床分期的肿瘤患者（初诊时治疗与晚期疾病治疗，或晚期初诊）。基于所有现有证据，许特莱细胞肿瘤似乎表现出与相应滤泡性肿瘤相似的生物学行为，尽管后者肿瘤可能有稍高的转移倾向。其生存率和治愈率低于乳头状癌，与滤泡状癌相当。DNA分析可能有助于预测临床行为；非整倍体肿瘤更常与恶性肿瘤的病理特征相关，可能遵循更具侵袭性的临床病程。然而，目前我们还不知道基于DNA分析的具体手术策略。肿瘤大小和细胞学特征的形态计量分析，对估计这些肿瘤的临床病程并没有特别的价值。
